In a drug safety communication issued on November 9, the U.S. FDA required all GLP-1 receptor agonist medications to add information regarding the potential risk of the rare eye disease NAION to the warnings and precautions section of their labels. The condition can cause sudden, painless monocular vision loss or even permanent blindness. The FDA described the associated risk as a potential increase.